Bone marrow stromal cells protect lymphoma B-Cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F11%3A%230001299" target="_blank" >RIV/65269705:_____/11:#0001299 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14740/11:00057005

Result on the web

<a href="http://dx.doi.org/10.1111/j.1365-2141.2011.08794.x" target="_blank" >http://dx.doi.org/10.1111/j.1365-2141.2011.08794.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1365-2141.2011.08794.x" target="_blank" >10.1111/j.1365-2141.2011.08794.x</a>

Result language

angličtina

Original language name

Bone marrow stromal cells protect lymphoma B-Cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance

Original language description

Rituximab improves the outcome of patients with non-Hodgkin lymphoma, but does not completely eradicate residual B-cell populations in the microenvironment of the bone marrow and lymph nodes. Adhesion to stromal cells can protect B-cells from apoptosis induced by chemotherapy drugs [(cell adhesion-mediated drug resistance (CAM-DR)]. A similar mechanism of resistance to rituximab has not, to our knowledge, been described. We tested the hypothesis that the microenvironment protects malignant B-cells fromrituximab-induced apoptosis, and that blocking these interactions with natalizumab, an antibody targeting VLA-4 (integrin alfa-4-beta-1/CD49d), can overcome this protection. VLA-4 is an adhesion molecule constitutively expressed on malignant B-cells andis important for pro-survival signalling in the bone marrow and lymph node microenvironment. The human bone marrow stromal cell line HS-5 was shown to strongly protect B-cell lymphoma cells from rituximab cytotoxicity, suggesting the exis

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT11218" target="_blank" >NT11218: Functional and structural changes of microRNAs in lymphoproliferative malignancies and their impact on prognosis and prediction of therapy response</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

British Journal of Haematology

ISSN

0007-1048

e-ISSN

—

Volume of the periodical

155

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

53-64

UT code for WoS article

000294919700005

EID of the result in the Scopus database

—